PIPR Stock Analysis: Piper Sandler Companies | NYSE
Capital Markets | NYSE, USA | Market Cap: 5.406m USD | 12M Return: -3.8% | US7240782091 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 38.9M
EPS Trend: 99.5%
Qual. Beats: 1
Rev. Trend: 97.0%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Piper Sandler Companies is a U.S.-headquartered investment bank and institutional securities firm that provides investment banking, institutional sales and trading, research, and advisory services to corporations, private equity groups, public entities, non-profits, and institutional investors in the United States and abroad. The company was founded in 1895 in Minneapolis, Minnesota, was previously known as Piper Jaffray Companies, and adopted its current name in January 2020.
The firm operates across several core business areas, including corporate advisory (mergers and acquisitions, equity and debt financings, private placements, restructuring, and debt capital markets advisory), public finance investment banking serving state and local governments, special districts, and sectors such as education, healthcare, housing, and transportation, as well as municipal financial advisory and loan placement, and over-the-counter derivative products. It also provides equity and fixed income trade execution, fundamental equity and macro research, and fixed income sales and trading solutions to clients including banks, registered investment advisors, credit unions, asset managers, and insurance companies.
In addition, Piper Sandler runs an alternative asset management platform that invests firm capital and manages outside capital through merchant banking and healthcare-focused funds. The company is listed on the NYSE under the ticker PIPR, is classified within the GICS Financials sector under the Investment Banking & Brokerage sub-industry, and as a mid-cap firm it is generally oriented toward middle-market advisory and capital markets transactions rather than the bulge-bracket global investment banks.
- M&A advisory revenue rises on private equity deal pipeline
- Municipal bond issuance volumes recover as Fed cuts rates
- Biotech IPO rebound lifts equity capital markets advisory fees
| Net Income: 307.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.26 > 0.02 and ΔFCF/TA 24.31 > 1.0 |
| NWC/Revenue: 27.02% < 20% (prev 25.97%; Δ 1.06% < -1%) |
| CFO/TA 0.27 > 3% & CFO 623.7m > Net Income 307.3m |
| Net Debt (30.8m) to EBITDA (515.6m): 0.06 < 3 |
| Current Ratio: 2.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.2m) vs 12m ago 0.48% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 98.03% > 50% (prev 79.60%; Δ 18.43% > 0%) |
| Interest Coverage Ratio: 150.5 > 6 (EBIT TTM 487.0m / Interest Expense TTM 3.23m) |
| A: 0.24 (Total Current Assets 1.09b - Total Current Liabilities 518.9m) / Total Assets 2.33b |
| B: 0.32 (Retained Earnings 734.0m / Total Assets 2.33b) |
| C: 0.23 (EBIT TTM 487.0m / Avg Total Assets 2.14b) |
| D: 1.81 (Book Value of Equity 1.37b / Total Liabilities 759.4m) |
| Altman-Z'' = 6.05 = AAA |
| DSRI: 0.77 (Receivables 296.4m/285.6m, Revenue 2.10b/1.56b) |
| GMI: 1.03 (GM 99.63% / 96.50%) |
| AQI: 0.63 (AQ_t 0.45 / AQ_t-1 0.71) |
| SGI: 1.35 (Revenue 2.10b / 1.56b) |
| TATA: -0.14 (NI 307.3m - CFO 623.7m) / TA 2.33b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of August 22, 2026, the stock is trading at USD 75.02 with a total of 343,202 shares traded. Over the past week, the price has changed by -1.93%, over one month by -2.87%, over three months by -6.87% and over the past year by -3.79%.
Current recommended Stop Loss: 71.60 (which is 4.6% or 1.4 ATR below the current price).
Piper Sandler Companies has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold PIPR.
- StrongBuy: 0
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 87.1 | 16.1% |
P/E Trailing = 17.7494
P/E Forward = 10.1112
P/S = 2.5559
P/B = 3.9383
P/EG = 1.2623
Revenue TTM = 2.10b USD
EBIT TTM = 487.0m USD
EBITDA TTM = 515.6m USD
Long Term Debt = 160.0m USD (estimated: total debt 175.0m - short term 15.0m)
Short Term Debt = 15.0m USD (from shortTermDebt, last quarter)
Debt = 335.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 160.0m
Net Debt = 30.8m USD (calculated: Debt 335.0m - CCE 304.2m)
Enterprise Value = 5.44b USD (5.41b + Debt 335.0m - CCE 304.2m)
Interest Coverage Ratio = 150.5 (Ebit TTM 487.0m / Interest Expense TTM 3.23m)
EV/FCF = 8.99x (Enterprise Value 5.44b / FCF TTM 604.5m)
FCF Yield = 11.12% (FCF TTM 604.5m / Enterprise Value 5.44b)
FCF Margin = 28.78% (FCF TTM 604.5m / Revenue TTM 2.10b)
Net Margin = 14.63% (Net Income TTM 307.3m / Revenue TTM 2.10b)
Gross Margin = unknown ((Revenue TTM 2.10b - Cost of Revenue TTM 73.6m) / Revenue TTM)
Tobins Q-Ratio = 2.34 (Enterprise Value 5.44b / Total Assets 2.33b)
Interest Expense / Debt = 0.97% (Interest Expense 3.23m / Debt 335.0m)
Taxrate = 24.91% (120.7m / 484.6m)
NOPAT = 365.7m (EBIT 487.0m * (1 - 24.91%))
Current Ratio = 2.09 (Total Current Assets 1.09b / Total Current Liabilities 518.9m)
Debt / Equity = 0.24 (Debt 335.0m / totalStockholderEquity, last quarter 1.37b)
Debt / EBITDA = 0.06 (Net Debt 30.8m / EBITDA 515.6m)
Debt / FCF = 0.05 (Net Debt 30.8m / FCF TTM 604.5m)
Total Stockholder Equity = 1.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.34% (Net Income 307.3m / Total Assets 2.33b)
RoE = 22.90% (Net Income TTM 307.3m / Total Stockholder Equity 1.34b)
RoCE = 32.42% (EBIT 487.0m / Capital Employed (Equity 1.34b + L.T.Debt 160.0m))
RoIC = 21.29% (NOPAT 365.7m / Invested Capital 1.72b)
WACC = 10.11% (E(5.41b)/V(5.74b) * Re(10.69%) + D(335.0m)/V(5.74b) * Rd(0.97%) * (1-Tc(0.25)))
Discount Rate = 10.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 54.76 | Cagr: 0.77%
[DCF] Terminal Value 72.50% ; FCFF base≈375.8m ; Y1≈430.8m ; Y5≈634.0m
[DCF] Fair Price = 102.6 (EV 7.28b - Net Debt 30.8m = Equity 7.25b / Shares 70.7m; r=10.11% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.46 | EPS CAGR: 34.33% | SUE: 1.10 | # QB: 1
Revenue Correlation: 97.02 | Revenue CAGR: 19.67% | SUE: 0.94 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.93 | Chg30d=-16.79% | Revisions=-62% | Analysts=5
EPS current Year (2026-12-31): EPS=4.63 | Chg30d=-1.66% | Revisions=-29% | GrowthEPS=+4.4% | GrowthRev=+10.8%
EPS next Year (2027-12-31): EPS=5.53 | Chg30d=-1.53% | Revisions=+0% | GrowthEPS=+19.4% | GrowthRev=+12.8%
[Analyst] Revisions Ratio: -44% (up=3, down=10)